STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.

Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.

Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.

Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.

Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.

Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.

Rhea-AI Summary
Abbott highlights four key factors for individuals with diabetes to safeguard heart health, emphasizing the importance of prioritizing health over neglecting it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
Rhea-AI Summary
Abbott extends partnership with Real Madrid to combat childhood malnutrition and promote healthy habits. The collaboration includes nutrition education, malnutrition screening, and nutritional guidance for athletes, aiming to improve the lives of children globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
partnership
-
Rhea-AI Summary
Abbott announces new data showing improved HbA1c results in Type 2 diabetes patients using GLP-1 medicines with FreeStyle Libre technology. The studies presented at a conference highlight significant benefits of combining these treatments for better glucose management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
Rhea-AI Summary
Abbott (ABT) declares a quarterly common dividend of 55 cents per share, marking the 401st consecutive dividend since 1924. The cash dividend will be paid on May 15, 2024, to shareholders of record on April 15, 2024. Abbott has raised its dividend for 52 years and is part of the S&P 500 Dividend Aristocrats Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
dividends
-
Rhea-AI Summary
Abbott's TriClip system for tricuspid regurgitation receives positive review from FDA advisory committee, showing safety, effectiveness, and quality-of-life benefits. The device has been approved in over 50 countries and has treated over 10,000 patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
none
-
Rhea-AI Summary
Abbott (NYSE:ABT) and Blood Centers of America (BCA) have partnered to launch a mixed reality experience for blood donors, designed to ease feelings of anxiety and increase donor retention. Results from the pilot study show that 68.4% of donors who reported pre-donation anxiety felt less anxious using mixed reality, and 89.2% of donors said they were likely to donate blood again. The technology aims to attract new donors and motivate a younger generation to give blood, addressing the global challenge of sustaining a reliable blood supply.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
Rhea-AI Summary
Abbott's emergency medicine pioneers have provided care for over 1.2 million people, including a pregnant woman in Tanzania who needed advanced health care during heavy rains. This demonstrates the company's commitment to global healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
Rhea-AI Summary
Abbott (NYSE:ABT) has announced the launch of its new PROTALITY™ brand, offering a high-protein nutrition shake to support weight loss while preserving muscle mass and good nutrition. The shake contains 30 grams of high-quality protein, 8 essential B vitamins, 4 grams of comfort fiber, 1 gram of sugar, 150 calories, and 25 vitamins and minerals. The product is now available online and at various retailers, catering to adults interested in pursuing weight loss while maintaining muscle health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
-
Rhea-AI Summary
Abbott's partnership with the Emergency Food Bank of Stockton, Calif. has led to encouraging results in delivering healthy meal boxes to people with diabetes. Nutrition educator Alex Marapao emphasizes the use of olive oil in cooking demonstrations, promoting healthy habits to combat diabetes. The mission is to share nutrition education that takes root in the community and grows healthy habits for generations to come.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
Rhea-AI Summary
A new study published in the journal Transfusion reveals that Abbott and Blood Centers of America's mixed reality technology for use during blood donation helps ease donors' feelings of anxiety and boosts the likelihood they will return to give blood again. The pilot study examined the experiences of 282 blood donors who tried mixed reality at 54 collection sites in Houston and the Quad Cities area in Iowa and Illinois. 68.4% of donors who reported pre-donation anxiety said the mixed reality experience helped ease their anxiety, and 89.2% of donors who tried mixed reality said they were likely to donate blood again. The mixed reality experience is an immersive digital experience designed to improve the blood donation process, attract new donors, and motivate a younger generation to give blood. It is now available at several donation sites across the country, including in New York, Houston, and the Chicago area.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none

FAQ

What is the current stock price of Abbott Laboratories (ABT)?

The current stock price of Abbott Laboratories (ABT) is $114.23 as of December 20, 2024.

What is the market cap of Abbott Laboratories (ABT)?

The market cap of Abbott Laboratories (ABT) is approximately 196.0B.

What does Abbott Laboratories specialize in?

Abbott Laboratories specializes in cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

What are some of Abbott’s recent product launches?

Recent product launches include the PROTALITY™ high-protein nutrition shake and the TriClip™ system for tricuspid valve repair.

How much of Abbott’s sales are generated outside the United States?

Approximately 60% of Abbott’s sales are generated outside the United States.

What is Abbott’s PROTALITY™ brand?

The PROTALITY™ brand is a high-protein nutrition shake designed to support weight loss while preserving muscle mass, addressing global health challenges like obesity.

How does Abbott support global health initiatives?

Abbott supports global health initiatives through strategic partnerships like their collaboration with the Real Madrid Foundation to reduce childhood malnutrition and promote healthy habits.

What is Abbott’s financial performance like?

Abbott has demonstrated robust financial performance, with strong Q1 2024 results and a consistent track record of dividend payouts, evidenced by its inclusion in the S&P 500 Dividend Aristocrats Index.

How many employees does Abbott have?

Abbott employs over 114,000 people worldwide.

Which continuous glucose monitoring system is Abbott known for?

Abbott is known for its FreeStyle Libre continuous glucose monitoring systems, which are widely recognized for their innovation in diabetes management.

What is Abbott's mission?

Abbott's mission is to help people live more fully at all stages of life by developing life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines.

In how many countries does Abbott operate?

Abbott operates in more than 160 countries worldwide.

Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

196.01B
1.72B
0.53%
77.7%
0.69%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ABBOTT PARK